Geoffrey M. Parker
Geoffrey M. Parker's purchase track record
How the stock did after each of Geoffrey M. Parker's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/12/2025 | PRGO | $106K | +3.1% | -21.2% | +8.7% |
| 8/18/2025 | PRGO | $100K | -40.4% | -36.5% | +6.1% |
| 5/12/2025 | PRGO | $95K | -17.5% | -46.0% | +16.9% |
| 1/30/2024 | ALLO | $683 | -23.3% | -17.5% | +10.4% |
| 6/13/2023 | PRGO | $331K | +3.2% | -11.5% | +6.3% |
| 3/6/2023 | PRGO | $190K | -9.2% | -2.4% | +11.1% |
| 12/16/2021 | PRGO | $184K | +5.0% | +2.4% | -21.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns. Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.
Transaction History
| PRGO | ▲ Buy | Option Exercise | 1,263 | $17K | 9/11/2026 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 607 | $8K | 9/11/2026 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 976 | $11K | 6/12/2026 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 469 | $5K | 6/12/2026 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 7,305 | $79K | 5/14/2026 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 3,507 | $38K | 5/14/2026 | View on chart |
| ALLO | ▼ Sell | Open Market | 24,001 | $42K | 2/2/2026 | View on chart |
| PRGO | ▲ Buy | Open Market | 7,500 | $106K | 11/12/2025 | View on chart |
| ALLO | ▼ Sell | Open Market | 36,744 | $46K | 10/21/2025 | View on chart |
| PRGO | ▲ Buy | Open Market | 4,375 | $100K | 8/18/2025 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 4,754 | $124K | 5/14/2025 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 9,904 | $258K | 5/14/2025 | View on chart |
| PRGO | ▲ Buy | Open Market | 3,500 | $95K | 5/12/2025 | View on chart |
| ALLO | ▼ Sell | Open Market | 4,361 | $8K | 2/3/2025 | View on chart |
| ALLO | ▲ Buy | Grant | 173,913 | $0 | 1/24/2025 | View on chart |
| ALLO | ▼ Sell | Tax Withholding | 36,404 | $103K | 10/21/2024 | View on chart |
| ALLO | ▲ Buy | Grant | 344,828 | $1.0M | 5/16/2024 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 8,764 | $265K | 5/15/2024 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 4,207 | $127K | 5/15/2024 | View on chart |
| ALLO | ▲ Buy | Open Market | 190 | $683 | 1/30/2024 | View on chart |
| ALLO | ▲ Buy | Grant | 29,400 | $0 | 1/25/2024 | View on chart |
| ALLO | ▲ Buy | Grant | 390,000 | $0 | 10/16/2023 | View on chart |
| ALLO | ▲ Buy | Grant | 400,000 | $0 | 10/16/2023 | View on chart |
| PRGO | ▲ Buy | Open Market | 10,000 | $331K | 6/13/2023 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 7,778 | $256K | 5/17/2023 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 3,734 | $123K | 5/17/2023 | View on chart |
| PRGO | ▲ Buy | Open Market | 5,000 | $190K | 3/6/2023 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 6,599 | $255K | 5/17/2022 | View on chart |
| PRGO | ▼ Sell | Tax Withholding | 3,168 | $122K | 5/17/2022 | View on chart |
| PRGO | ▲ Buy | Open Market | 5,000 | $184K | 12/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Perrigo valuation seen as cheap but burdened by high debt
A recent Seeking Alpha article notes that Perrigo's shares appear cheap compared with peers. The piece highlights that the company carries a sizable debt load, which could limit financial flexibility. This contrast may lead investors to weigh the low valuation against the debt risk when evaluating the company.
Perrigo valuation seen as cheap but burdened by high debt. A recent Seeking Alpha article notes that Perrigo's shares appear cheap compared with peers. The piece highlights that the company carries a sizable debt load, which could limit financial flexibility. This contrast may lead investors to weigh the low valuation against the debt risk when evaluating the company.